DESTINY-Breast03 trial: some questions remain - Authors' reply

Affiliations

¹ Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Electronic address: shurvitz@mednet.ucla.edu.
² European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
³ Daiichi Sankyo, Basking Ridge, NJ, USA.
⁴ International Breast Cancer Center, Pangaea Oncology, Quironsalud Group, Barcelona, Spain; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.

Comment

Sara A Hurvitz et al. Lancet. 2023.

. 2023 May 20;401(10389):1653-1654.

doi: 10.1016/S0140-6736(23)00681-5.

¹ Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Electronic address: shurvitz@mednet.ucla.edu.
² European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
³ Daiichi Sankyo, Basking Ridge, NJ, USA.
⁴ International Breast Cancer Center, Pangaea Oncology, Quironsalud Group, Barcelona, Spain; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.

No abstract available

Comment on

DESTINY-Breast03 trial: some questions remain.
Hindié E. Hindié E. Lancet. 2023 May 20;401(10389):1652. doi: 10.1016/S0140-6736(23)00679-7. Lancet. 2023. PMID: 37210114 No abstract available.
DESTINY-Breast03 trial: some questions remain.
Altundag K. Altundag K. Lancet. 2023 May 20;401(10389):1652-1653. doi: 10.1016/S0140-6736(23)00680-3. Lancet. 2023. PMID: 37210115 No abstract available.
DESTINY-Breast03 trial: some questions remain.
Di Cosimo S, Apolone G, Cappelletti V, Torri V. Di Cosimo S, et al. Lancet. 2023 May 20;401(10389):1653. doi: 10.1016/S0140-6736(23)00685-2. Lancet. 2023. PMID: 37210116 No abstract available.